Article
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2004
Yen Wan-Ching, Corpuz Manny R, Prudente Rene Y, Cooke Tracy A, Bissonnette Reid P, Negro-Vilar Andrés, Lamph William W
Abstract excerpt
PURPOSE: Paclitaxel is an important anticancer agent for the treatment of non-small cell lung cancer (NSCLC). However, its use in cancer therapy is limited by development of acquired drug resistance. The goal of this study was to determine the effect of bexarotene on development of acquired paclitaxel resistance in NSCLC. EXPERIMENTAL DESIGN: Human NSCLC Calu3 cells were repeatedly treated in culture with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.